



# Cancer Reporting in California

## Appendix F Site-Specific Data Items (SSDIs)

### California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedures

**Twenty-Fifth Edition**

Version 1.0, May 2025

**Prepared By:**

California Cancer Registry

Cancer Informatics and IT Systems Unit

**Editors:**

Mary K. Brant, B.S., ODS-C

Donna M. Hansen, ODS-C

Janine Smith, B.S., ODS-C

**State of California:**

Department of Health Services

Dr. Mark Damesyn, CDRSB, Chief

## Appendix F: Index to Site-Specific Data Items (SSDIs)

A Site-Specific Data Item (SSDI) is based on primary site, AJCC chapter, the EOD schema, or the Summary Stage schema. SSDI's have their own data item name and number and can be collected for as many sites, chapters, and/or schemas as needed. Each Site-Specific Data Item (SSDI) applies only to selected schemas.

**Source:** The [Site-Specific Data Item \(SSDI\) Manual](#) is to be used for detailed descriptions, rationales, coding instructions, and site-specific coding rules.

### CCR Specific Guidelines

- **The list below includes all SSDI data items that are required by the CCR for CoC Facilities Only.**
  - Non-CoC facilities may choose to voluntarily collect CoC required SSDIs.
- **SSDIs not mentioned in the list below are required by the CCR from ALL facilities.**
- All SSDIs must be supported by text documentation in the abstract.

<b>SSDI Data Item Name</b>	<b>CCR Years Required by CoC Facilities</b>
AFP Post-Orchiectomy Lab Value	2018+
AFP Pre-Orchiectomy Lab Value	2018+
AFP Pre-Orchiectomy Range	2018+
AFP Pretreatment Interpretation	2018+
AFP Pretreatment Lab Value	2018+
Bilirubin Pretreatment Total Lab Value	2018+
Bilirubin Pretreatment Unit of Measure	2018+
Chromosome 3 Status	2018+
Chromosome 8q Status	2018+
Creatinine Pretreatment Lab Value	2018+
Creatinine Pretreatment Unit of Measure	2018+
Estrogen Receptor Percent Positive or Range	2018+
Estrogen Receptor Total Allred Score	2018-2022
Extranodal Extension Clin (non-Head and Neck)	2018+
Extranodal Extension Head and Neck Clinical	2018+
Extranodal Extension Path (non-Head and Neck)	2018+
Extravascular Matrix Patterns	2018+
Gleason Score Clinical	2018+
Gleason Score Pathological	2018+

Gleason Tertiary Pattern	2018+
hCG Pre-Orchiectomy Lab Value	2018+
hCG Post-Orchiectomy Lab Value	2018+
HER2 IHC Summary	2018-2020
HER2 ISH Dual Probe Copy Number	2018-2020
HER2 ISH Dual Probe Ratio	2018-2020
HER2 ISH Single Probe Copy Number	2018-2020
HER2 ISH Summary	2018-2020
International Normalized Ratio Prothrombin Time	2018+
Ki-67	2018+ for breast (required for all facilities for NET schemas)
KIT Gene Immunohistochemistry	2018+
LDH Upper Limits of Normal	2018+
LN Assessment Method Femoral-Inguinal	2018+
LN Assessment Method Para-Aortic	2018+
LN Assessment Method Pelvic	2018+
LN Distant Assessment Method	2018+
LN Distant Mediastinal, Scalene	2018+
Microvascular Density	2018+
Mitotic Count Uveal Melanoma	2018+
Number of Examined Para-Aortic Nodes	2018+, 2021+ for cervix sarcoma
Number of Examined Pelvic Nodes	2018+, 2021+ for cervix sarcoma
Number of Positive Para-Aortic Nodes	2018+, 2021+ for cervix sarcoma
Number of Positive Pelvic Nodes	2018+, 2021+ for cervix sarcoma
Oncotype DX Recurrence Score-DCIS	2018+
Oncotype DX Risk Level-DCIS	2018+
Oncotype DX Risk Level-Invasive	2018+
Percent Necrosis Post Neoadjuvant	2018+
Primary Sclerosing Cholangitis	2018+
Progesterone Receptor Percent Positive or Range	2018+
Progesterone Receptor Total Allred Score	2018-2022

Response to Neoadjuvant Therapy	2018+
Tumor Growth Pattern	2022+ (required for all facilities 2018-2021)